Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Operating Expenses (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Other Operating Expenses for 6 consecutive years, with $13.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 12.05% year-over-year to $13.7 million, compared with a TTM value of $53.4 million through Dec 2025, up 12.03%, and an annual FY2025 reading of $53.4 million, up 12.03% over the prior year.
  • Other Operating Expenses was $13.7 million for Q4 2025 at Xeris Biopharma Holdings, roughly flat from $13.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $16.3 million in Q3 2024 and bottomed at $1.8 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $9.4 million, with a median of $9.6 million recorded in 2022.
  • The sharpest move saw Other Operating Expenses plummeted 80.47% in 2021, then soared 392.0% in 2022.
  • Year by year, Other Operating Expenses stood at $5.4 million in 2021, then surged by 65.51% to $9.0 million in 2022, then grew by 14.21% to $10.3 million in 2023, then grew by 18.56% to $12.2 million in 2024, then increased by 12.05% to $13.7 million in 2025.
  • Business Quant data shows Other Operating Expenses for XERS at $13.7 million in Q4 2025, $13.7 million in Q3 2025, and $14.6 million in Q2 2025.